



Tuberculosis Country Profile 2021 Thailand

Source: Global tuberculosis report 2021. Geneva: World Health Organization

Disclaimer: Tuberculosis country profiles are generated automatically based on data reported by countries and which are held in WHO's global TB database.

Tuberculosis profile: Thailand

Population 2020: 70 million

Estimates of TB burden*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	105 000 (79 000-134 000)	150 (113-192)
HIV-positive TB incidence	9 900 (7 400-13 000)	14 (11-18)
HIV-negative TB mortality	10 000 (7 200-13 000)	14 (10-19)
HIV-positive TB mortality	2 000 (1 400-2 700)	2.9 (2.1-3.9)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2020	82% (64-110)
TB patients facing catastrophic total costs, 2020	31% (27-35)
TB case fatality ratio (estimated mortality/estimated incidence), 2020	12% (7-17)

TB case notifications, 2020

Total new and relapse	85 837
- % tested with rapid diagnostics at time of diagnosis	38%
- % with known HIV status	82%
- % pulmonary	85%
- % bacteriologically confirmed ^A	63%
- % children aged 0-14 years	1%
- % women (aged ≥15 years)	32%
- % men (aged ≥15 years)	67%
Total cases notified	87 525

TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive	6 631	9.4%
- on antiretroviral therapy	5 560	84%

Drug-resistant TB care**, 2020

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^A	71%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^A	83%
Laboratory-confirmed cases - MDR/RR-TB ^{AA}	1 302
Patients started on treatment - MDR/RR-TB ^{AAA}	1 204
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^{AA}	65
Patients started on treatment - pre-XDR-TB or XDR-TB ^{AAA}	62
MDR/RR-TB cases tested for resistance to any fluoroquinolone	638

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2019	85%	87 083
Previously treated cases, excluding relapse, registered in 2019	63%	1 655
HIV-positive TB cases registered in 2019	75%	6 694
MDR/RR-TB cases started on second-line treatment in 2018	63%	910
XDR-TB cases started on second-line treatment in 2018	81%	21

TB preventive treatment, 2020


% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	84% (77-92)

TB financing

National TB budget, 2021 (US\$ millions)	30
- Funding source, domestic	82%
- Funding source, international	18%
- unfunded	0%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)




HIV-negative TB mortality

(Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2020

(Number)




Cases attributable to five risk factors, 2020

(Number)



Total budget

(US\$ millions)



* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone

^A Calculated for pulmonary cases only

^{AA} Includes cases with unknown previous TB treatment history

^{AAA} Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed